clinical trial · NCT06039579
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
ViiV Healthcare·phase2·completed·n = 44
HIV InfectionsVH4004280VH4011499VH4004280 Matching PlaceboVH4011499 Matching PlaceboAntiretroviral therapy
brief summary
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
started
Oct 25, 2023
primary completion
Jun 24, 2024
completion
Jun 24, 2024
last updated
Sep 30, 2025
official title
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Phase 2a Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Investigational Capsid Inhibitor Monotherapy in HIV-1 Infected Treatment-Naïve Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol